克罗恩病治疗市场- 按治疗（药物{抗炎药、免疫抑制剂、抗生素、退烧药}、营养治疗、手术）、剂型（口服、肠胃外）、年龄组、最终用途、全球预测2024 - 2032

在全球发炎性肠道疾病 (IBD) 盛行率不断上升的推动下，克隆氏症治疗市场预计 2024 年至 2032 年复合年增长率将达到 4%。根据克隆氏症和结肠炎基金会 2023 年的情况说明书，大约有 160 至 310 万美国人受到 IBD 的影响。意识和诊断能力的提高导致更多病例被发现，从而增加了对有效治疗的需求。医学研究和技术的进步也带来了新的疗法和生物製剂，为患者带来了希望。例如，2024年7月，FDA批准了Stelara（杨森免疫学）的成分ustekinumab-ttwe用于所有适应症，包括严重干癣、干癣性关节炎、克隆氏症和溃疡性结肠炎。

此外，对个人化医疗的关注正在改变克隆氏症的治疗方式。随着对疾病病理生理学的了解不断加深，治疗方法也越来越适合个体的遗传和分子特征。这种方法提高了治疗效果和患者治疗效果，进一步推动市场成长。

整个克隆氏症治疗产业根据治疗、剂型、年龄层、最终用途和地区进行分类。

由于营养治疗在控制症状和改善患者预后方面发挥关键作用，因此到 2032 年将获得巨大的关注。营养治疗有助于解决吸收不良问题、维持适当的营养状态并减少发炎。客製化饮食计划，例如肠内营养和排除饮食，因其诱导缓解和补充药物治疗的潜力而日益受到认可。这种方法不仅支持整体健康和生活质量，而且还减少了对药物的依赖，药物可能会产生不利影响。

由于人们对疾病的认识不断提高以及早期诊断的益处，儿科细分市场预计到 2032 年将占据显着的市场份额。儿科患者的克隆氏症带来了独特的挑战，包括需要对发育中的身体安全有效的治疗。研究的进步为儿童提供了量身定制的治疗方法，包括针对生长和疾病管理的适合年龄的药物和营养干预措施。对早期介入和个人化护理的日益重视正在推动对儿科患者专业治疗和支援服务的需求。

受该地区疾病盛行率上升、医疗基础设施改善以及人们对克罗恩病认识不断提高的推动，亚太地区克罗恩病治疗市场规模将在 2032 年大幅扩大。医疗保健服务范围的扩大和医疗技术的投资正在促进先进治疗方案的可用性，包括生物製剂和标靶治疗。此外，该地区对研发的日益关注正在促进创新和提高护理品质。随着经济的持续发展和医疗保健系统的发展，亚太市场有望大幅成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 克隆氏症患者病率增加
    • 诊断技术的进步
    • 增加药物开发的研究与开发活动
    • 提高人们对克隆氏症的认识
  • 产业陷阱与挑战
    • 疾病管理的复杂性
    • 缺乏治疗方法
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按处理方式，2021 - 2032

• 主要趋势
• 药物
  • 抗发炎剂
  • 免疫抑制剂
  • 抗生素和退烧药
  • 其他药物
• 营养治疗
• 手术

第 6 章：市场估计与预测：按剂型，2021 - 2032

• 主要趋势
• 口服
• 注射用

第 7 章：市场估计与预测：按年龄划分，2021 - 2032

• 主要趋势
• 儿科
• 成人
• 老年科

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 医院和诊所
• 家庭护理设置
• 其他最终用户

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Biogen
• Boehringer Ingelheim GmbH
• Bristol Myerr Squibb
• Eli Lilly and Company
• Janssen Pharmaceuticals (Johnson & Johnson)
• Merck & Co. Inc
• Novartis AG
• Pfizer, Inc.
• Salix Pharmaceuticals, Inc.
• Takeda Pharmaceutical Industries Limited
• Viatris Inc. (Mylan N.V.)

Crohn's Disease Treatment Market is anticipated to record 4% CAGR during 2024-2032, backed by the increasing global prevalence of inflammatory bowel disease (IBD). According to the 2023 fact sheet by Crohn's & Colitis Foundation, around 1.6 to 3.1 million Americans are affected by IBD. Improved awareness and diagnostics are leading to more cases being identified, which boosts the demand for effective treatments. Advances in medical research and technology have also led to new therapies and biologics, offering hope for patients. For example, in July 2024, the FDA granted approval for ustekinumab-ttwe, a component of Stelara (Janssen Immunology), for all its indications, including severe psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Additionally, the focus on personalized medicine is changing how Crohn's disease is treated. As the understanding of the disease's pathophysiology improves, treatments are becoming more tailored to individual genetic and molecular profiles. This approach improves treatment effectiveness and patient outcomes, further driving market growth.

The overall Crohn's disease treatment industry is classified based on treatment, dosage form, age group, end-use, and region.

The nutritional therapy segment will gain significant traction through 2032, due to its critical role in managing symptoms and improving patient outcomes. Nutritional therapy helps address malabsorption issues, maintain proper nutritional status, and reduce inflammation. Customized dietary plans, such as enteral nutrition and exclusion diets, are increasingly recognized for their potential to induce remission and complement pharmacological treatments. This approach not only supports overall health and quality of life but also reduces reliance on medications, which can have adverse effects.

The pediatric segment is poised to hold a notable market share by 2032, backed by the improved awareness of disease and benefits of early diagnosis. Crohn's disease in pediatric patients presents unique challenges, including the need for treatments that are safe and effective for a developing body. Advances in research have led to tailored therapeutic approaches for children, including age-appropriate medications and nutritional interventions that address both growth and disease management. The growing emphasis on early intervention and personalized care is driving the demand for specialized treatments and support services for pediatric patients.

Asia Pacific Crohn's disease treatment market size will expand substantially through 2032, driven by increasing disease prevalence, improved healthcare infrastructure, and rising awareness of Crohn's disease across the region. The expansion of healthcare access and investment in medical technology are facilitating the availability of advanced treatment options, including biologics and targeted therapies. Additionally, a growing focus on R&D within the region is fostering innovation and enhancing the quality of care. As economic development continues and healthcare systems evolve, the Asia Pacific market is poised for substantial growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of crohn's disease
    • 3.2.1.2 Advancement in diagnostic techniques
    • 3.2.1.3 Increasing research & development activities for drug development
    • 3.2.1.4 Increased awareness about crohn's disease
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Complexity of disease management
    • 3.2.2.2 Lack of curative treatments
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 Anti-inflammatory agents
  • 5.2.2 Immunosuppressants
  • 5.2.3 Antibiotics and antipyretics
  • 5.2.4 Other medications
• 5.3 Nutritional therapy
• 5.4 Surgery

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pediatric
• 7.3 Adult
• 7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals & clinics
• 8.3 Homecare settings
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Amgen Inc.
• 10.3 AstraZeneca Plc
• 10.4 Biogen
• 10.5 Boehringer Ingelheim GmbH
• 10.6 Bristol Myerr Squibb
• 10.7 Eli Lilly and Company
• 10.8 Janssen Pharmaceuticals (Johnson & Johnson)
• 10.9 Merck & Co. Inc
• 10.10 Novartis AG
• 10.11 Pfizer, Inc.
• 10.12 Salix Pharmaceuticals, Inc.
• 10.13 Takeda Pharmaceutical Industries Limited
• 10.14 Viatris Inc. (Mylan N.V.)